Generative models for structure-based drug design have strong potential to accelerate early-stage drug discovery by enabling the conditional generation of target-specific molecules. However, a major bottleneck is that generated compounds are frequently difficult or impossible to synthesize, limiting their direct experimental validation and utility. We address this by optimizing for membership in make-on-demand chemical libraries, ensuring that generated molecules can be directly purchased and tested. To this end, we apply reinforcement learning to a pocket-conditioned generative molecular model, steering generated molecules toward two large make-on-demand spaces: Enamine REAL and Freedom 4.0. We compare an offline, preference-based strategy (direct preference optimization, DPO) and an online RL strategy (DiffusionNFT) across single-target and multi-target settings. In single-target optimization for KRAS, the fraction of unique purchasable candidates rises from 10.0% to 25.5% for Enamine REAL and from 4.3% to 12.1% for Freedom 4.0, while drug-likeness and docking-based affinity proxies are preserved. In multi-target optimization, DPO achieves consistent improvements across diverse protein targets, including a 23-fold increase for the challenging CDK4 pocket. These results demonstrate that RL alignment can substantially improve the experimental accessibility of SBDD candidates without sacrificing structural or chemical quality.
No takes yet. Share an insight, caveat, or question.
Neeser et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: